Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

ClinicalTrials.gov ID: NCT00232141

Public ClinicalTrials.gov record NCT00232141. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With HIV Neuropathy.

Study identification

NCT ID
NCT00232141
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
302 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • pregabalin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2005
Primary completion
Oct 31, 2007
Completion
Oct 31, 2007
Last update posted
Feb 8, 2021

2005 – 2007

United States locations

U.S. sites
41
U.S. states
18
U.S. cities
32
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35294
Pfizer Investigational Site Phoenix Arizona 85023
Pfizer Investigational Site Little Rock Arkansas 72207
Pfizer Investigational Site Los Angeles California 90025
Pfizer Investigational Site Los Angeles California 90028
Pfizer Investigational Site Sacramento California 95817-1460
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site San Francisco California 94117
Pfizer Investigational Site Stanford California 94301
Pfizer Investigational Site West Hollywood California 90069
Pfizer Investigational Site Denver Colorado 80262
Pfizer Investigational Site Miami Florida 33133
Pfizer Investigational Site Pensacola Florida 32504-5719
Pfizer Investigational Site Safety Harbor Florida 34695
Pfizer Investigational Site Vero Beach Florida 32960
Pfizer Investigational Site West Palm Beach Florida 33407
Pfizer Investigational Site Atlanta Georgia 30309
Pfizer Investigational Site Honolulu Hawaii 96816
Pfizer Investigational Site Chicago Illinois 60611
Pfizer Investigational Site Chicago Illinois 60612
Pfizer Investigational Site Baltimore Maryland 21287-7609
Pfizer Investigational Site Boston Massachusetts 02215
Pfizer Investigational Site Springfield Massachusetts 01107
Pfizer Investigational Site St Louis Missouri 63110-1010
Pfizer Investigational Site St Louis Missouri 63110
Pfizer Investigational Site New York New York 10018
Pfizer Investigational Site New York New York 10021
Pfizer Investigational Site New York New York 10029
Pfizer Investigational Site Rochester New York 14642
Pfizer Investigational Site Portland Oregon 97209
Pfizer Investigational Site Philadelphia Pennsylvania 19104
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Dallas Texas 75204
Pfizer Investigational Site Dallas Texas 75208-4234
Pfizer Investigational Site Dallas Texas 75208
Pfizer Investigational Site Dallas Texas 75219
Pfizer Investigational Site Dallas Texas 75390-9036
Pfizer Investigational Site Longview Texas 75605
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Seattle Washington 98104
Pfizer Investigational Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00232141, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 8, 2021 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00232141 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →